Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CITY THERAPEUTICS, INC.CTY · Entity 184066 | Chief Medical Officer | October 15, 2026 | October 16, 2026 |
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, CHIEF MEDICAL OFFICER | December 03, 2024 | December 05, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CITY THERAPEUTICS, INC.
Report date October 15, 2026 · Filed October 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 228,743 |
Reported balance
Holding disclosure · report date 2026-10-15 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 228,743 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.84 · Expires 2035-05-12 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: 25% of the shares underlying this option vested on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.36 · Expires 2036-06-02 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-10-15 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The shares underlying this option vest in 48 equal monthly installments following June 3, 2026, subject to the Reporting Person's continued service on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares underlying this option vested on March 31, 2026, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service on each such vesting date.
F2: The shares underlying this option vest in 48 equal monthly installments following June 3, 2026, subject to the Reporting Person's continued service on each such vesting date.
Editas Medicine, Inc.
Report date December 03, 2024 · Filed December 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,354 |
Reported balance
After 2024-12-03 transaction · row 1
1 source rowRow 1 · 2024-12-03 · Sale · Disposed 541 · Balance 133,354 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $2.0507 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2024. The sale does not represent a discretionary trade by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $2.0507 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 03, 2024 Filed Dec 5, 2024 21:37 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 541 | $2.08 | $1,123.77 |
DisclosureSEC source: 0001650664-24-000124 · wk-form4_1733434638.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · EVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,354 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $2.0507 to $2.0783. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 04, 2024 Filed Sep 6, 2024 20:20 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 518 | $3.42 | $1,773.99 |
DisclosureSEC source: 0001650664-24-000105 · wk-form4_1725654028.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · EVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,895 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $3.4246 to $3.4501. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2024 Filed Jul 22, 2024 21:01 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 6,619 | $5.21 | $34,455.87 |
DisclosureSEC source: 0001650664-24-000087 · wk-form4_1721682068.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · EVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,413 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 18, 2024. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $5.1650 to $5.2058. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2024 Filed Jun 6, 2024 20:16 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 511 | $5.50 | $2,808.25 |
DisclosureSEC source: 0001650664-24-000075 · wk-form4_1717704962.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · EVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,032 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 04, 2024 Filed Mar 6, 2024 00:54 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 20,327 | $9.42 | $191,425.46 |
DisclosureSEC source: 0001650664-24-000013 · wk-form4_1709686469.xml · nonDerivative · entry 4 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,543 F4 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022 and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2024. The sale does not represent a discretionary trade by the Reporting Person. F5 · price: This transaction was executed in multiple trades at prices ranging from $9.1036 to $9.4298. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 00:54 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 152,800 | $0.00 Strike: $10.53 | $0.00 |
DisclosureSEC source: 0001650664-24-000013 · wk-form4_1709686469.xml · derivative · entry 5 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 152,800 Underlying: Common Stock · 152,800 shares Expires 2034-03-01 F6 · derivative.exercise_date: This option was granted on March 2, 2024 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2024 through March 2, 2028. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 00:54 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 19,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000013 · wk-form4_1709686469.xml · nonDerivative · entry 3 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 161,870 F3 · kind: Reflects the vesting, upon the achievement of a business development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 00:54 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 19,458 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000013 · wk-form4_1709686469.xml · nonDerivative · entry 2 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,413 F2 · kind: Reflects the vesting, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on July 18, 2022. Read SEC document |
| March 02, 2024 Filed Mar 6, 2024 00:54 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 50,900 | $0.00 | $0.00 |
DisclosureSEC source: 0001650664-24-000013 · wk-form4_1709686469.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 122,955 F1 · kind: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2025 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2028. Read SEC document |
| July 19, 2023 Filed Jul 21, 2023 20:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 4,317 | $8.80 | $37,989.60 |
DisclosureSEC source: 0001415889-23-011382 · form4-07212023_040701.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,055 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 14, 2022 and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on July 18, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 54,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001415889-23-004314 · form4-03062023_040307.xml · derivative · entry 2 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 Underlying: Common Stock · 54,000 shares Expires 2033-03-01 F2 · derivative.exercise_date: This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 21:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004314 · form4-03062023_040307.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,372 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:36 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 171,602 | $0.00 Strike: $14.99 | $0.00 |
DisclosureSEC source: 0001415889-22-007838 · form4-07202022_010742.xml · derivative · entry 2 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,602 Underlying: Common Stock · 171,602 shares Expires 2032-07-17 F2 · derivative.exercise_date: This option was granted on July 18, 2022 and is scheduled to vest over four years, with 25% of the shares to vest on July 18, 2023 and the remaining 75% of the shares scheduled to vest in equal monthly installments thereafter through July 18, 2026. Read SEC document |
| July 18, 2022 Filed Jul 20, 2022 20:36 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 58,372 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-007838 · form4-07202022_010742.xml · nonDerivative · entry 1 Mei Baisong · CIK 0001938499 · SVP, CHIEF MEDICAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,372 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years in equal yearly installments of one-fourth of the shares, with the first such installment to vest on July 18, 2023 continuing through July 18, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.